Zynex Inc. $ZYXI Shares Bought by Deutsche Bank AG

Deutsche Bank AG raised its position in Zynex Inc. (NASDAQ:ZYXI) by 172.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,796 shares of the company’s stock after acquiring an additional 12,540 shares during the period. Deutsche Bank AG owned approximately 0.07% of Zynex worth $44,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ZYXI. Tower Research Capital LLC TRC lifted its stake in shares of Zynex by 138.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company’s stock worth $27,000 after buying an additional 1,975 shares during the period. Alhambra Investment Management LLC acquired a new stake in shares of Zynex during the first quarter worth $30,000. Corton Capital Inc. acquired a new stake in shares of Zynex during the first quarter worth $52,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Zynex by 19.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 52,317 shares of the company’s stock worth $115,000 after buying an additional 8,661 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Zynex by 9.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 19,333 shares of the company’s stock worth $155,000 after buying an additional 1,660 shares during the period. 29.68% of the stock is currently owned by institutional investors and hedge funds.

Zynex Stock Performance

Shares of Zynex stock opened at $1.64 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.62 and a quick ratio of 0.45. The firm has a fifty day moving average price of $2.05 and a 200 day moving average price of $2.82. Zynex Inc. has a 1 year low of $1.23 and a 1 year high of $9.42. The stock has a market cap of $49.69 million, a PE ratio of -1.74 and a beta of 1.02.

Analyst Ratings Changes

ZYXI has been the subject of several research reports. LADENBURG THALM/SH SH upgraded shares of Zynex from a “neutral” rating to a “buy” rating and set a $3.70 price objective for the company in a research note on Friday, August 1st. Royal Bank Of Canada lowered their price objective on shares of Zynex from $4.00 to $3.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 15th. Finally, HC Wainwright downgraded shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.90.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.